Trial Profile
Clinical study of autologous tumor lysate-pulsed dendritic cell therapy after resection of lung cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs HSP105 peptide-loaded dendritic cell vaccine (Primary) ; Dendritic cell vaccines
- Indications Lung cancer
- Focus Adverse reactions
- 05 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 15 Jun 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 15 Jun 2011 New trial record